Role of the B1 Bradykinin Receptor and gC1qR/p33 in Angioedema

Fleur Bossi, Francesco Tedesco

Research output: Contribution to journalArticlepeer-review


Patients affected by angioedema (AE) are subject to asymmetric, nonerythematous, nonpruritic, localized, transient, episodic swelling of deeper layers or submucosal tissues of the skin, oropharyngolaryngeal tissue, and/or gastrointestinal wall. The nonapeptide bradykinin (BK) may be largely responsible for the vascular permeability seen in most AE. During AE attacks, activation of the serine proteases leads to the release of BK. Enzymes expressed on the endothelial cell membrane can metabolize BK, producing the agonist of the B1R, which can then be upregulated by proinflammatory stimuli, suggesting that the blockade of B1R and B2R, or gC1q/p33, may provide novel therapeutic targets.

Original languageEnglish
Pages (from-to)535-544
Number of pages10
JournalImmunology and Allergy Clinics of North America
Issue number4
Publication statusPublished - Nov 2013


  • Angioedema
  • BK 1 receptor
  • BK 2 receptor
  • GC1qR/p33
  • Vascular leakage

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Role of the B1 Bradykinin Receptor and gC1qR/p33 in Angioedema'. Together they form a unique fingerprint.

Cite this